The next key steps in the construction of the Biotech Development Center will be the finalisation of the building’s interior and the installation of the equipment. The Biotech Development Center is expected to be fully operational by 2023.

With the existing production sites in Corsier-sur-Vevey and Aubonne as well as the future Biotech Development Center, Western Switzerland confirms its leading position for the production and development of Merck’s biotech drugs. This latest investment of CHF 270 million reflects the strategic importance of Switzerland for Merck, where the company employs more than 2’500 people across eight sites.